APA

Lauseker M., Pfirrmann M., Hoffmann V. S. & Hasford J. (20120906). Comment on "Second-generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia in whom imatinib therapy has failed" Haematologica 2011;96(12):1779-82. : Haematologica.

Chicago

Lauseker Michael, Pfirrmann Markus, Hoffmann Verena S and Hasford Joerg. 20120906. Comment on "Second-generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia in whom imatinib therapy has failed" Haematologica 2011;96(12):1779-82. : Haematologica.

Harvard

Lauseker M., Pfirrmann M., Hoffmann V. S. and Hasford J. (20120906). Comment on "Second-generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia in whom imatinib therapy has failed" Haematologica 2011;96(12):1779-82. : Haematologica.

MLA

Lauseker Michael, Pfirrmann Markus, Hoffmann Verena S and Hasford Joerg. Comment on "Second-generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia in whom imatinib therapy has failed" Haematologica 2011;96(12):1779-82. : Haematologica. 20120906.